Impax’s Parkinson’s Drug NDA Rejected Due to Manufacturing Issues

Drug Industry Daily
A A
The FDA’s rejection of Impax Pharmaceuticals’ extended-release capsule Rytary for the treatment of idiopathic Parkinson’s disease points to continuing problems at a California manufacturing site.

To View This Article:

Login

Subscribe To Drug Industry Daily